Friday, July 10, 2026
🇺🇸 FDA

pharma · Hypertension · Breast Neoplasms

Pfizer

Pfizer drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Website Investor relations
New York 10017, US HQ
103,316 Employees
EMA registrant Type
Company details
Status
Public
HQ
New York 10017, US
Employees
103,316
Programs
98
Drugs
80
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Drug Pipeline

Pfizer pipeline

Portfolio lens on 80 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Pfizer drug portfolio — 80 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

80 compounds

  1. acetaminophen

    US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.

    Target
    Fatty-acid amide hydrolase 1
    Mechanism
    Cyclooxygenase inhibitor

  2. alzheimer

    Development asset linked to Pfizer in public FDA and regional records.

  3. amlodipine

    Cardiovascular system (C09)

    Cardiovascular system (C09) compound in Pfizer's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.

    Mechanism
    Voltage-gated L-type calcium channel blocker

  5. amlodipine besylate

    US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.

    Target
    Voltage-gated L-type calcium channel
    Mechanism
    Voltage-gated L-type calcium channel blocker

  6. anidulafungin

    Antiinfectives for systemic use (J02)

    US regulatory status: approved. Molecular target: 1,3-beta-glucan synthase.

    Target
    1,3-beta-glucan synthase
    Mechanism
    1,3-beta-glucan synthase inhibitor

  7. apixaban

    Blood and blood forming organs (B01)

    US regulatory status: approved. Molecular target: Coagulation factor X.

    Target
    Coagulation factor X
    Mechanism
    Coagulation factor X inhibitor

  8. artesunate

    Antiparasitic products (P01)

    US regulatory status: approved. Mechanism: Unknown.

    Mechanism
    Unknown

  9. atorvastatin

    Development asset linked to Pfizer in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.

    Mechanism
    HMG-CoA reductase inhibitor

  10. atorvastatin calcium

    US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

    Target
    3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Mechanism
    HMG-CoA reductase inhibitor

  11. avelumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.

    Target
    Programmed cell death 1 ligand 1
    Mechanism
    Programmed cell death 1 ligand 1 other

  12. azithromycin

    US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Bacterial 70S ribosome inhibitor

  13. bevacizumab

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A inhibitor

  14. bosutinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Tyrosine-protein kinase ABL1.

    Target
    Tyrosine-protein kinase ABL1
    Mechanism
    Tyrosine-protein kinase ABL inhibitor

  15. brentuximab

    Development asset linked to Pfizer in public FDA and regional records.

  16. brentuximab vedotin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Tubulin.

    Target
    Tubulin
    Mechanism
    Tubulin inhibitor

  17. calcium

    US regulatory status: approved.

  18. capecitabine

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: DNA.

    Target
    DNA
    Mechanism
    Thymidylate synthase inhibitor

  19. ceftaroline fosamil

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  20. ceftazidime

    Antiinfectives for systemic use (J01)

    US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor

  22. celecoxib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.

    Target
    Prostaglandin G/H synthase 2
    Mechanism
    Cyclooxygenase-2 inhibitor

  23. chemotherapy

    Development asset linked to Pfizer in public FDA and regional records.

  24. chlorothiazide

    US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.

    Target
    Solute carrier family 12 member 3
    Mechanism
    Thiazide-sensitive sodium-chloride cotransporter inhibitor

  25. combination

    Development asset linked to Pfizer in public FDA and regional records.

  26. covid-19 vaccine (inactivated, adjuvanted, adsorbed)

    Antiinfectives for systemic use (J07)

    Antiinfectives for systemic use (J07) compound in Pfizer's portfolio. Mechanism: Biological vaccine - induces immune response.

    Mechanism
    Biological vaccine - induces immune response

  27. dexmedetomidine

    Nervous system (N05)

    Nervous system (N05) compound in Pfizer's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.

    Mechanism
    Adrenergic receptor alpha-2 agonist

  28. disitamab

    Development asset linked to Pfizer in public FDA and regional records.

  29. dose

    Development asset linked to Pfizer in public FDA and regional records.

  30. enzalutamide

    Antineoplastic and immunomodulating agents (L02)

    US regulatory status: approved. Molecular target: Androgen receptor.

    Target
    Androgen receptor
    Mechanism
    Androgen Receptor antagonist

  31. eplerenone

    US regulatory status: approved. Molecular target: Mineralocorticoid receptor.

    Target
    Mineralocorticoid receptor
    Mechanism
    Mineralocorticoid receptor antagonist

  32. etanercept

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Tumor necrosis factor.

    Target
    Tumor necrosis factor
    Mechanism
    TNF-alpha inhibitor

  33. gabapentin

    US regulatory status: approved. Molecular target: Voltage-gated calcium channel.

    Target
    Voltage-gated calcium channel
    Mechanism
    Voltage-gated calcium channel modulator

  34. hema-

    Development asset linked to Pfizer in public FDA and regional records.

  35. hydrochlorothiazide

    US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.

    Target
    Solute carrier family 12 member 3
    Mechanism
    Thiazide-sensitive sodium-chloride cotransporter inhibitor

  36. induction

    Development asset linked to Pfizer in public FDA and regional records.

  38. injection

    Development asset linked to Pfizer in public FDA and regional records.

  39. inotuzumab ozogamicin

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: B-cell receptor CD22.

    Target
    B-cell receptor CD22
    Mechanism
    CD22 binding agent

  40. ketorolac tromethamine

    US regulatory status: approved. Molecular target: Cyclooxygenase.

    Target
    Cyclooxygenase
    Mechanism
    Cyclooxygenase inhibitor

  41. malignant

    Development asset linked to Pfizer in public FDA and regional records.

  42. management

    Development asset linked to Pfizer in public FDA and regional records.

  43. maraviroc

    Antiinfectives for systemic use (J05)

    US regulatory status: approved. Molecular target: C-C chemokine receptor type 5.

    Target
    C-C chemokine receptor type 5
    Mechanism
    C-C chemokine receptor type 5 antagonist

  44. meningococcal

    Development asset linked to Pfizer in public FDA and regional records.

  45. methotrexate

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Dihydrofolate reductase inhibitor

  46. moxifloxacin

    Development asset linked to Pfizer in public FDA and regional records.

  47. olmesartan

    Development asset linked to Pfizer in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.

    Target
    Type-1 angiotensin II receptor
    Mechanism
    Type-1 angiotensin II receptor antagonist

  48. palbociclib

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: CDK6/cyclin D1.

    Target
    CDK6/cyclin D1
    Mechanism
    Cyclin-dependent kinase 4/cyclin D1 inhibitor

  49. pegaptanib

    Sensory organs (S01)

    Sensory organs (S01) compound in Pfizer's portfolio. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A antagonist

  50. pegaptanib sodium

    US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.

    Target
    Vascular endothelial growth factor A, long form
    Mechanism
    Vascular endothelial growth factor A antagonist

  51. pemetrexed disodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  52. pemetrexed sodium

    US regulatory status: approved. Molecular target: Dihydrofolate reductase.

    Target
    Dihydrofolate reductase
    Mechanism
    Thymidylate synthase inhibitor

  53. placebo

    Development asset linked to Pfizer in public FDA and regional records.

  54. postoperative

    Development asset linked to Pfizer in public FDA and regional records.

  55. pregabalin

    Nervous system (N02)

    US regulatory status: approved. Molecular target: Voltage-gated calcium channel.

    Target
    Voltage-gated calcium channel
    Mechanism
    Voltage-gated calcium channel modulator

  56. protocol

    Development asset linked to Pfizer in public FDA and regional records.

  58. rc48

    Development asset linked to Pfizer in public FDA and regional records.

  59. rimegepant

    Nervous system (N02)

    US regulatory status: approved. Molecular target: Calcitonin gene-related peptide type 1 receptor.

    Target
    Calcitonin gene-related peptide type 1 receptor
    Mechanism
    Calcitonin gene-related peptide type 1 receptor antagonist

  60. sasanlimab

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Programmed cell death protein 1.

    Target
    Programmed cell death protein 1
    Mechanism
    Programmed cell death protein 1 antagonist

  61. sildenafil

    Genito-urinary system and sex hormones (G04)

    Genito-urinary system and sex hormones (G04) compound in Pfizer's portfolio. Mechanism: Phosphodiesterase 5A inhibitor.

    Mechanism
    Phosphodiesterase 5A inhibitor

  62. sildenafil citrate

    US regulatory status: approved. Molecular target: cGMP-specific 3',5'-cyclic phosphodiesterase.

    Target
    cGMP-specific 3',5'-cyclic phosphodiesterase
    Mechanism
    Phosphodiesterase 5A inhibitor

  63. sirolimus

    Antineoplastic and immunomodulating agents (L04)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  64. standard

    Development asset linked to Pfizer in public FDA and regional records.

  65. statin

    Development asset linked to Pfizer in public FDA and regional records.

  66. sunitinib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  67. sunitinib malate

    US regulatory status: approved. Molecular target: Macrophage colony-stimulating factor 1 receptor.

    Target
    Macrophage colony-stimulating factor 1 receptor
    Mechanism
    Vascular endothelial growth factor receptor inhibitor

  68. tablet

    Development asset linked to Pfizer in public FDA and regional records.

  69. talazoparib

    Antineoplastic and immunomodulating agents (L01)

    Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.

    Target
    Poly [ADP-ribose] polymerase 2
    Mechanism
    Poly [ADP-ribose] polymerase 2 inhibitor

  70. tamoxifen

    Development asset linked to Pfizer in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.

    Mechanism
    Estrogen receptor alpha modulator

  71. temsirolimus

    Antineoplastic and immunomodulating agents (L01)

    US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.

    Target
    Peptidyl-prolyl cis-trans isomerase FKBP1A
    Mechanism
    FK506-binding protein 1A inhibitor

  72. therapy

    Development asset linked to Pfizer in public FDA and regional records.

  73. timolol

    US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.

    Target
    Beta-1 adrenergic receptor
    Mechanism
    Beta-2 adrenergic receptor antagonist

  74. tofacitinib citrate

    US regulatory status: approved. Molecular target: Janus Kinase (JAK).

    Target
    Janus Kinase (JAK)
    Mechanism
    Janus Kinase (JAK) inhibitor

  75. treatment

    Development asset linked to Pfizer in public FDA and regional records.

  76. urea c-13

    US regulatory status: approved. Mechanism: Diagnostic agent.

    Mechanism
    Diagnostic agent

  77. vaccine

    Development asset linked to Pfizer in public FDA and regional records.

  78. valdecoxib

    Musculo-skeletal system (M01)

    US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.

    Target
    Prostaglandin G/H synthase 2
    Mechanism
    Cyclooxygenase-2 inhibitor

  79. zavegepant

    Development asset linked to Pfizer in public FDA and regional records. Molecular target: Calcitonin-gene-related peptide receptor, CALCRL/RAMP1.

    Target
    Calcitonin-gene-related peptide receptor, CALCRL/RAMP1
    Mechanism
    Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist

  80. ziprasidone

    Development asset linked to Pfizer in public FDA and regional records. Mechanism: Dopamine D2 receptor antagonist.

    Mechanism
    Dopamine D2 receptor antagonist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.